Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A. Mackintosh, Gregory Keir, Lauren K. Troy, Anne E. Holland, Christopher Grainge, Daniel C. Chambers, Debra Sandford, Helen E. Jo, Ian Glaspole, Margaret Wilsher, Nicole S.L. Goh, Paul N. Reynolds, Sally Chapman, Steven E. Mutsaers, Sally de Boer, Susanne Webster, Yuben Moodley, Tamera J. Corte

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

Original languageEnglish
Pages (from-to)105-135
Number of pages31
JournalRespirology
Volume29
Issue number2
Early online date11 Jan 2024
DOIs
Publication statusPublished - Feb 2024

Fingerprint

Dive into the research topics of 'Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision'. Together they form a unique fingerprint.

Cite this